Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 2/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 2/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4810705 | 0.85 | KMT2A (0.38) | — | |
| SCHEMBL17043164 | 0.74 | ACHE (0.42) | HSD17B1BRD4MAOBHRH3 | |
| SCHEMBL4816146 | 0.73 | HSD17B1 (0.54) | HSD17B1 | |
| SCHEMBL866242 | 0.69 | HSD17B1 (0.51) | HSD17B1BRD4MAOB | |
| SCHEMBL25612285 | 0.69 | L3MBTL1 (0.43) | — | |
| SCHEMBL23580895 | 0.68 | FDPS (0.42) | — | |
| SCHEMBL30279737 | 0.68 | FDPS (0.42) | — | |
| SCHEMBL9741669 | 0.68 | TUBB4A (0.38) | HSD17B1BRD4MAOBHRH3 | |
| SCHEMBL17043171 | 0.68 | BRD4 (0.41) | HSD17B1BRD4MAOBHRH3 | |
| SCHEMBL3082824 | 0.67 | ACHE (0.54) | HSD17B1BRD4MAOBHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7320986-B2 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBOTT LABORTORIES (US) | 2008-01-22 | — | — | US | disclosed |
| US-20040259904-A1 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBVIE INC. | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259904-A1 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | TK1, MAP3K19, MAP3K20 | HSD17B1 2373/4885ALOX5AP 4744/4885FEN1 821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.